Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.
The Merck Global Health Innovation Fund invested $6 million in OpGen on the same day the microbial genetics specialist announced it will acquire AdvanDx, a maker of molecular tests for blood cultures.
While the European Medicines Agency said it "does not question that the benefits of HPV vaccines outweigh their risks," on Monday it announced a safety review of the shots that have thus far failed to live up to expectations partly due to safety concerns and a sex-related stigma.
Merck's Keytruda and Bristol-Myers Squibb's Opdivo may be two of the most watched drugs in pharma right now. That's not only because both are breakthrough immunotherapy cancer treatments, but also because both are racing to win additional indications. And when it comes to marketing, each one is playing its advantage.
Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Wading into what has become an "argy-bargy" political issue, Merck CEO Ken Frazier gave his two cents on why Australians miss out on new drugs.
Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.